As cell and gene therapies (CGTs) accelerate toward broader clinical use, the industry faces a deceptively simple but existential question: how can companies be absolutely sure that the cells infused into a patient are the same cells that were originally collected from them?
According to Will Moss, founder and CEO of Seal, an execution system used by CGT companies from process development through manufacturing, the answer lies in fixing what he describes as one of the most underestimated operational risks in advanced therapies: the chain of identity.
“In cell and gene therapy, chains of identity prove the cells you treat a patient with are the same cells that originally came from that patient,” Moss says. Because many CGTs are autologous, derived from a patient’s own cells, the manufacturing process becomes a bespoke journey spanning weeks or months, multiple facilities, and dozens of handoffs.
That journey typically begins with a blood draw at a clinical site and continues through lab processing, genetic modification, storage, shipping, and eventual reinfusion. “You must maintain perfect traceability from blood draw to infusion,” Moss says. “That’s extraordinarily hard when so many people, systems, and locations are involved.”
The challenge is compounded by the fragmented nature of today’s infrastructure. Clinics, contract development and manufacturing organizations (CDMOs), couriers, and labs often rely on a patchwork of labels, spreadsheets, LIMS, emails, and manual reconciliations. Under time pressure, staff might relabel samples or work around rigid software.
Fragmented, retrospective, and easy-to-bypass tools
“These tools are fragmented, retrospective, and easy to bypass,” Moss says. “Identity is often checked ex post facto rather than enforced in real time.”
The stakes could not be higher. A single identity failure could result in a patient receiving the wrong cells, triggering severe immune reactions or worse. Regulators also demand step-by-step proof that a therapy is what a company claims it to be. Failure to demonstrate that proof can halt trials, reject batches, or cost companies years of work and millions of dollars.
Beyond safety and compliance, Moss sees chain of identity as a bottleneck to scale. Unlike traditional drugs, CGT validation and documentation scale linearly with patients. “Each new therapy increases system complexity,” he says, calling identity one of the top reasons programs stall between Phase II and commercialization.
Moss argues that the solution is not more training or additional standard operating procedures, but systems that assume human error and are designed to catch it instantly. “Identity verification has to be continuous, enforced, and provable by design,” he says.
That means embedding identity directly into workflows, using a single source of truth across all steps, and automatically generating audit trails. Errors should trigger immediate hard stops, requiring investigation before work can continue. Batch records should be dynamic, adapting in real time to the variability of living cells. Quality review, Moss adds, must happen concurrently rather than after the fact to accommodate short shelf lives.
Ultimately, Moss envisions “vein-to-vein visibility,” a unified view from patient collection to patient infusion that connects clinical sites, manufacturers, and logistics partners.
“If we want these therapies to reach more patients,” he says, “we have to move beyond artisanal processes. Chain of identity isn’t paperwork—it’s the foundation of trust, safety, and scale.”

